In the present study, we have attempted to develop an eating habits scale for gestational diabetes women for supporting diet therapy and maintaining QoL during pregnancy. By searching 552 previous articles, we developed a gestational diabetes scale consist of 44 items related to dietary life in women with gestational diabetes. Next, we introduced this scale into two surveys for evaluating the reliability and validity of the scale. The first survey conducted conforming factor analysis and exploratory factor analysis based on data from a purposive sample of 235 patients. The second survey confirmed the stability of data from 81patients by test-retest. The patients consisted of gestational diabetes women in diet. Scale development involved several phases, including item development, reliability testing, criterion-related validity, and construct validity testing. Construct validity was tested with exploratory factor analysis and resulted in 14 items with a 2-factor solution: “Diet therapy for gestational diabetes” and “Subjective health of gestational diabetes women”. The total score and subscale scores of eating habits scale showed excellent internal consistency. In addition, confirmatory factor analysis indicated that a 2-factor model for 235 patients. Cronbach’s α coefficient was 0.906 for the overall scale, confirming general internal consistency. The model showed approximately good fit to the data by confirmatory factor analysis (GFI = 0.924, AGFI = 0.883, RMSEA = 0.064). A significant correlation was observed between eating habits scale and SF-8 Physical Component Summary (r = 0.039) as well as SF-8 Mental Component Summary (r = 0.047). Sufficient criterion-related validity was not confirmed by the HbA1c value (r = -0.092). We could not show enough validity of eating habits scale for gestational diabetes women in this study. However, high reliability indicated by the stability indicated with repeated testing has shown, therefore, this scale may useful for evaluating eating habits for gestational diabetes women.

Disclosure

M. Amaya: None. K. Sekijima: None. Y. Koyama: None. T. Yoshioka: None. N. Ohara: None. T. Yamada: None. S. Soda: None. K. Yahata: None. H. Sone: Research Support; Novo Nordisk, Astellas Pharma Inc., Kyowa Kirin Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Ono Pharmaceutical Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Co., Ltd. K. Asazawa: None. N. Arimori: None.

Funding

Japan Society for the Promotion of Science (17K17476)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.